Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buspirone for Esophageal Function in Systemic Sclerosis
NCT02363478Phase 1Completed
- Sponsor
- Laiko General Hospital
- Start
- Dec 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of buspirone in systemic sclerosis (SSc), sponsored by Laiko General Hospital. Primary endpoints: Amplitude of Contractions at the Distal Part of the Esophagus at 4 weeks, Resting Lower Esophageal Sphincter (LES) Pressure at 4 weeks and 4 more. Started Dec 2014; status: completed.
02
Drugs
buspirone
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT02363478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02363478.